Title of Invention


Abstract A cosmetic method for treating aged, wrinked and/or photodamaged skin is provided through topical application of a composition which comprises 8-prenylnaringenin.
Full Text FORM2
(39 of 1970)
(See section 10; rule 13)
1. Title of the invention. - TOPICAL COMPOSITION
2. Applicant - (a) Hindustan Lever Limited
b) of Hindustan Lever House, 165/166, Backbay Reclamation, Mumbai 400 020, Maharashtra, India.
(c) an Indian Company ;
The following specification (particularly) describes the nature of this invention (and the manner in which it is to be performed)


This invention relates to a cosmetic method of improving the condition end appearance of skin and to the use of 8-prenylnaringenin in the preparation of topical compositions for improving the condition and appearance of skin.
Skin is subject to deterioration through dermatological disorders, environmental abuse (wind, air conditioning, central heating, etc.) or through the normal aging process (chronoaging) which may be accelerated by exposure of skin to sun (photoaging). In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously.
Consumers are increasingly seeking "anti-aging" cosmetic products which treat or delay the visible signs of chronoaging and photoaging skin such as wrinkles, lines, sagging, hyperpigmentation and age spots.
Consumers also frequently seek other benefits from cosmetic products in addition ,to antiraging The sencept of "sensitive skin" has also raised "the consumer demand for cosmetic products which improve the appearance and. condition of sensitive, dry and/or flaky skin and to soothe red, and/or irritated skin. Consumers also desire cosmetic products which treat spots, pimples, blemishes etc.
8-prenylnaringenin as a substance is known. For example, in The Journal of Endocrinology & Metabolism Vol. S3 No. 6, Milligan et al., "Identification of a potent phytoestrogen in hops and beer", 8-prenylnaringenin is recognized as being a potent phytoestrogen. The structure of 8-prenylnaringenin


is also

shown in that paper. 8-prenylnaringenin occurs in hops, from which it can be isolated and

We have now surprisingly found further undisclosed properties of 8-prenylnaringenin, which are useful in cosmetic compositions for topical application to skin to provide previousiy undisclosed skin care benefits.
We have now found that effective treatment and prevention of normal skin conditions due to chronoaging or photoaging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, may be obtained through the application of cosmetic compositions to the skin which comprise 3-prenyinaringenin. or derivatives thereof. We have also found that the use of 3-prenyinaringenin in cosmetic compositions advantageously provides further skin benefits in addition to anti-aging such as for soothing sensitive and/or irritated skin.
In a first aspect the invention comprises a topical composition for application to the human skin comprising an effective amount of 8-prenyinaringenin.
According to a further aspect of the present invention there is a method of providing at least one cosmetic skin care benefit selected from: treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin; soothing irritated, red and/or sensitive skin; improving skin texture, smoothness and/or firmness; the method comprising applying to the skin a topical composition comprising 8-prenvlnaringenin and/or derivatives thereof.


The present invention also encompasses the use of 8-prenylnaringenin .and/or derivatives thereof in the preparation of a topical composition for providing at least one skin care benefit selected from treating/preventing wrinkling, sagging, aged and/or photodamaged skin; boosting collagen deposition in skin, boosting decorin production in skin; soothing irritated, red and/or sensitive skin; improving skin texture, smoothness and/or firmness.
Another aspect of the present invention provides 8-prenylnaringenin for use in the treatment of wrinkling, sagging, aged and/or photodamaged skin; for boosting collagen deposition in skin; for boosting decorin production in skin; for soothing irritated, red and/or sensitive skin; and for improving skin texture, smoothness and/or firmness.
The inventive methods and use of 8-prenylnarihgenin thus provide anti-aging benefits which result in the promotion of smooth and supple skin with improved elasticity and a reduced or delayed appearance of wrinkles and aged skin, with improved skin colour. A general improvement in the appearance, texture and condition, in particular with respect to the radiance, clarity and general.youthfull. appearance of skin may be achieved. The . inventive methods and uses are also beneficial for soothing and calming sensitive and/or irritated skin. Thus the inventive methods advantageously provide a wide range of skin care benefits.
These benefits might include improved hydration, texture/tone, smoothness, silkiness, firmness, strength/resilience and radiance.
The term "treating" as used herein includes within its scope reducing, delaying and/or preventing the above mentioned


skin conditions such as wrinkled, aged, photodamaged, and/or irritated skin and generally enhancing the quality of skin and improving" its-" appearance and texture by preventing or reducing wrinkling and increasing flexibility, firmness, smoothness, suppleness and elasticity of the skin. The cosmetic methods and the uses of S-prenylnaringenin and/or derivatives according to the invention may be useful for treating skin which is already in a wrinkled, aged, photo-damaged and irritated condition or for treating youthful skin to prevent or reduce those aforementioned deteriorative changes due to the normal aging/photo aging process.
The invention also includes derivatives of the free molecule which thus comprise 8-prenylnaringenin moieties.
The active 8-prenylnaringenin to be employed in accordance with the present invention is present in the topical composition in an effective amount. Normally the total amount of the active is present in an amount between 0.0001% and 50% by weight of the composition. More preferably the amount is from 0.001% to 10% and most preferably from 0.01% to 1% in order to maximize benefits at a minimum cost:
The composition used according to the invention also comprises a dermatblogically/cosmetically acceptable vehicle to act as a dilutant, dispersant or carrier for the active. The vehicle may comprise materials commonly employed in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners, powders, propellents and the like.
The vehicle will usually form from 5% to 39.9%, preferably from 25% to 80% by weight of the composition, and can, in


the absence of other cosmetic adjuncts, form the balance of the composition.
Besides the active, 3-prenylnaringenin, other specific skin-benefit actives such as sunscreens, skin lightening agents and skin tanning agents nay also be included. The vehicle may also further include adjuncts such as perfumes, cpacifiers, preservatives, colourants and buffers.
To prepare the topical composition used in the method of the present invention, the usual manner for preparing skin care products may be employed. . The . active components are generally incorporated in a dermatologicaliy acceptable carrier in conventional manner. The active components can suitably first be dissolved or dispersed in a portion of the water or another solvent or liquid to be incorporated in the composition. The preferred compositions are oil-in-water or water-in-oil emulsions.
The composition may be in the form of conventional skin-care products such as a cream, gel or lotion or zhe like. The composition can also be in the form of a so-called "wash-off" . product e.g. a bath or shower gel, possibly containing a delivery system for the actives to promote adherence to the skin during rinsing. Most preferably the product is a "leave-on" product; a product to be applied to the skin without a deliberate rinsing "step soon after its application to the skin.
The composition may packaged in any suitable manner such as in a jar, a bottle, tube, roll-ball, or the like, in the conventional manner.


The method of the present invention may be carried out one or more times daily to the skin which requires treatment. The imorovemenf in skin appearance will usually become visible after 1 to 3 months, depending on skin condition, the concentration of the active components used in the inventive method, the amount of composition used and the frequency with which it is applied. In general, a small quantity of the composition, for example from 0.1 to 5 ml is applied to the skin from a suitable container or applicator and spread over and/or rubbed into the skin using the hands or fingers or a suitable device. A rinsing step may optionally follow depending on whether the composition is formulated as a "leave-on" or a "rinse-off" product.

In order that the present invention may be more readily understood, the. following examples are given, by way of illustration only, with reference to the accompanying" drawings, in which:

Figure 1 shows the effect of 6-prenylnaringenin on
decorin synthesis;
Figure 2 shows the effect of 8-prenylnaringenin on
procollagen synthesis and-
Figure 3 shows the effect of 8-prenyinaringenin on
the reduction of PGS2 expression.
The first example demonstrates the anti-aging benefits of 3-prenylnaringenin.


It is known from our co-pending European application no. 99908355.8 that topical retinoic acid treatments can be used to cause upregulation of procollagen I and decorin in vivo. To this end, the passages under the heading "Identification of procollagen I and decorin upregulation in skin in vivo following topical retinoic acid treatment for comparative purposes" in that application are incorporated herein in their entirety.
Example 1
Procedure For Measuring Procollagen-I and Decorin Synthesis In Human Dermal Fibroblasts
Preparation of Dermal Fibroblast Conditioned Medium
Primary human foreskin fibroblasts at passage 2 (P2) were seeded into 12-well plates at 10000 cells/cm2 and maintained for 24 hours in an atmosphere of 5% carbon dioxide and 4% oxygen in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal calf seruin. After this time the cells were washed with serum " free DMEM and then incubated. in fresh serum free DMEM for a further 60 hours The fibroblast monolayers were then"" washed again with serum free DMEM. Test reagents and vehicle controls were added to the cells in triplicate in a final volume of 0.4ml/well fresh serum free DMEM and incubated for a further 24 hours. This fibroblast conditioned medium was either analyzed immediately or snap frozen in liquid nitrogen and stored at -70°C for future analysis. The cells were then counted and data from the dot-blot analysis subsequently standardized to cell number.


Dot Blot Assay for Procoliagen-I and Decorin Protein in Dermal Fibroblast Conditioned Medium
Samples of conditioned medium from dermal fibroblasts treated with vehicle (as a control) or test reagents were supplemented with 20mM dithiothreitcl (1:10 dilution of 200mM stock solution) and 0.1% sodium dodecylsulphate (1:100 dilution of 10% stock solution), mixed well and then incubated at 75°C for 2 minutes. A standard for the assay was generated by serial dilution of neat fibroblast conditioned medium from fibroblasts seeded at 10000 cells/cm2 in a 175cm2 flask and maintained in serum free D.MEM as described above.
Assay samples were subsequently applied in triplicate to a
pre-wetted sheet of Immobilon-P transfer membrane using the
96-well Bio-Dot Apparatus from Bio-Rad as described in the
manufacturer"s guidelines. Approximately 200ul of medium
was applied per well. The medium was allowed to filter
through the membrane under gravity (30 minutes) after which
the membrane was washed twice with PBS (200ul). These PBS
washes were allowed to filter through the membrane under
gravity (2x15" minutes). The Bio-Dot apparatus was then
attached to a vacuum manifold and a third and final PBS wash carried out under suction. The apparatus was disassembled, the membrane removed and quickly cut as required before being placed in blocking buffer overnight at 4°C.
Membranes prepared for decorin analysis were blocked with 3% (w/v) BSA/ 0.1% (v/v) Tween 20 in PBS, whilst these for procollagen-I analysis were blocked with 5% (w/v) ncn fat dried milk powder/ 0.05% Tween 20 in PBS. The following day, the membranes were probed with 1:10000 dilution of


primary antibodies to either human procollagen-I (MAB1912; rat- monoclonal," Chemicon Int. Inc., Temecula, CA) or human decorin (rabbit polyclonal; Biogenesis) for 2 hours at room temperature. The membranes were subsequently washed with T55/ 0,05% Tween 20 (3x5 minutes) and then incubated with 1:1000 dilution of 325I-conjugated anti-rat or anti-rabbit F(ab")2 fragments (Amersham) as required for 1 hour at room temperature.
Following this the Immobilon strips were again washed with T3S/Tween 20 (3x5 minutes) before being allowed to dry in air at room temperature. The dried membranes were wrapped in cellophane and exposed to a Molecular Dynamics storage phosphor screen for 16-18 hours. At the end of r.his time the exposed screen was scanned by a phosphorimager (Molecular Dynamics Phosphorimager SF) using ImageQuant™ software. Dot intensity was assessed" by computer-assisted image analysis using the quantification tools in ImageQuant™, standardized to cell number and the effects cf various test reagents on decorin and procollagen-I synthesis were determined relative to a vehicle treated control value of 100 arbitrary units.
The results of the assays are shown graphically in figures 1 and 2. In order to normalize the results the effects cf the test substance was determined relative to a vehicle treated control value of 100 arbitrary units.
For comparison, a trial was performed with retinoic acid to assess its effect on decorin synthesis in human dermal fibroblasts.


The results. in. figures 1 and 2 indicate that 8-prenylnaringenin significantly upregulates the synthesis of both procollagen-I and decorin in human dermal fibroblasts as compared to the control.
The level of decorin in skin is associated with improved condition and appearance of skin. Increasing the level of decorin in skin is important for controlled and correct deposition of collagen in skin which is associated with many skin benefits such as wrinkle effacement and dermal repair of photodamaged skin.
The comparative trial with retincic acid (lum) showed an upregluation of decorin, 138 3 14(p=0.035, n=4), as determined relative to a vehicle treated control value of 100 arbitrary units. Surprisingly, the data thus further indicates that the magnitude of the upregulation of and decorin synthesis in human dermal fibroblasts effected by exceeds that of the bench-mark anti-aging dermal repair active, retincic acid.
Further comparative tests were conducted to compare the
upregulation of Procollagen I and Decorin using 8-
prenylnaringenin and other known estrogens or phytoestrogens.
The same protocols as described above were used in the tests.
Initially, results were obtained for the known estrogens/phytoestrogens in media which contained Phenol Red (itself having estrogenic activity) . The tests were then repeated for 8-prenylnaringenin and the known


estrogens/phytoestrogens in media which was free of Phenol Red. The results are set out below in Tables 1 and 2.
Table 1
Percentage increases in the levels of Procollagen I and Decorin secreted from human fibroblasts cultured in media containing phenol red.

Active at i uM containing phenol (in media red) Procollagen I Decorin
17-p-Estradiol 107.7 121
Resveratrol 102.1 113.1
Daidzein ■ 118 98.9
Genistein . 124 114
Data are presented in arbitrary units relative to a vehicle control value of 100.
Table 2
Percentage increases in . the levels of Procollagen I and Decorin secreted from human fibroblasts cultured in media minus phenol red.

Active at 1 uM (phenol red-free media) Procollagen I Decorin
8-Prenylnarningenin 350 800
17-p-Estradiol 170 130
■ 152 252
Genistein 200 24 0
Data are presented in arbitrary units relative to a vehicle control value of 100.


From the above test results, it is clear that 8-Prenylnaringenir. is a much better inducer of Procollagen I and Decorin than other known estrogens or phytoestrogens themselves. Without wishing to be bound by theory, it is believed ti. - 8-Prenylnaringenin is not acting like a phytoestrogen, but may be promoting the synthesis of the two repair markers through another molecular pathway.
Exampie 2
Fibroblast PGE2 Assay
The following example demonstrates that S-prenylnarigenin can effectively reduce the basal levels of prostaglandin E2 (?GE2) secreted by fibroblasts in vitro.
Primary human foreskin fibroblasts at passage 2 (?2) were seeded into 96-well plates at 10000 cells/well and maintained for 24 hours in an atmosphere of 5% carbon dioxide in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum. 8-prenylnaringenin was dissolved in ethanol was added to fresh cell media (final concentration 1% EtOH in DMEM, supplemented with 10% foetal calf serum) and added to the cells in the wells in triplicate and incubated for a. further 24 hours. Phorbal myristate acetate (PMA) (Sigma) was added to the media and the cells incubated for a further 24 hours. PMA acts as the stressor that induces oxidative stress and inflammatory responses in cells. The fibroblasts/media were then analyzed as described - below immediately or snap frozen in liquid nitrogen and stored at -70°C for future analysis.


Prostaglandin E2 (PGE2) assay
Volumes of 50ul culture medium were taken for ?GS2 assay after gently shaking the culture "plate. PGE2 levels in the medium were determined with a Biotrak PGE2 immunoassay kit (Amersham, UK) . The assay is based on the competition between unlabelled PGE2 in the sample and a fixed quantity of horseradish peroxidase labeled ?GE2 for a limited amount of fixed PGE2 specific antibody. Concentrations of unlabelled sample PGE 2 are determined according to a standard curve, which was obtained at the same time.
The anti-inflammatory potential of the test compounds was assessed by the ability of the compounds to reduce the basal
levels of secreted PGE2 as compared to the control. The
results that were obtained are shown in Figure 3.
PGE2 is a well known mediator of inflammation in the skin see Greaves et al "Prostagludus,leukotriemes,phospholipase, platelet actuating factor and cytokines: an integrated approach to inflammation of human skin", Arch. Dermatol. Res. (1988) 280 [supp]: 533-541. The results indicated that fibroblasts treated with 8-prenylnaringenin produce less of the pro-inflammato-ry - prostaglandin "PGE2/ thereby reducing the inflammatory potential of the skin.
Example 3

The formulation below describes an oil in water cream suitable for the methods and uses according to the present invention. The percentages indicated are by weight of the composition.


Brij 56 is cetyl alcohol POE (10) Alfol 16RD is cetyl alcohol
Example 4
The formulation below describes an emulsion cream according to the present invention.


3oth the above topical compositions of example 3 and 4 may provide an effective cosmetic treatment to improve the appearance of wrinkled, aged, photo-damaged, and/or irritated skin, when applied to skin that has deteriorated through the aging or photoageing or when applied to youthful skin to help prevent or delay such deteriorative changes. The compositions can be processed in conventional manner.


We claim:
1. A topical composition comprising:
(a) 8-prenylanaringenin in an amount between 0.0001% and 50% by weight of the composition; and
(b) a dermatologically acceptable vehicle.
2. A topical composition as claimed in claim 1 wherein the 8-
prenylanaringenin is present at a level of 0.0001 to 1.0% by weight of the
Dated this 8th day of May 2003
Dr.Sanchita Ganguli Of S. Majumdar & Co. Applicant"s Agent




488-mumnp-2003-cancelled page(19-03-2004).pdf







488-mumnp-2003-form 19(23-06-2003).pdf

488-mumnp-2003-form 1a(08-05-2003).pdf

488-mumnp-2003-form 2(granted)-(19-03-2004).doc

488-mumnp-2003-form 2(granted)-(19-03-2004).pdf

488-mumnp-2003-form 3(08-05-2003).pdf

488-mumnp-2003-form 5(08-05-2003).pdf

488-mumnp-2003-genral power of attorney(08-05-2003).pdf



488-mumnp-2003-petition under rule 138(19-11-2004).pdf

488-mumnp-2003-power of attorney(27-03-2001).pdf


Patent Number 211355
Indian Patent Application Number 488/MUMNP/2003
PG Journal Number 45/2007
Publication Date 09-Nov-2007
Grant Date 26-Oct-2007
Date of Filing 08-May-2003
# Inventor's Name Inventor's Address
PCT International Classification Number A 61 K 7/48
PCT International Application Number PCT/EP01/12732
PCT International Filing date 2001-11-02
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 0027769.9 2000-11-14 U.K.